aTyr Pharma (NASDAQ:LIFE) Stock Crosses Above Two Hundred Day Moving Average of $1.54

aTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.70. aTyr Pharma shares last traded at $1.61, with a volume of 359,600 shares traded.

Analyst Upgrades and Downgrades

LIFE has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of aTyr Pharma in a research report on Friday, March 15th. Royal Bank of Canada reduced their price objective on shares of aTyr Pharma from $19.00 to $16.00 and set an "outperform" rating for the company in a research note on Friday, March 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $23.67.

aTyr Pharma Stock Down 1.2 %

The firm has a market cap of $108.02 million, a PE ratio of -1.65 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The business has a fifty day moving average price of $1.85 and a two-hundred day moving average price of $1.54.

aTyr Pharma (NASDAQ:LIFE - Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.02). On average, analysts anticipate that aTyr Pharma, Inc. will post -0.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LIFE. FMR LLC boosted its holdings in aTyr Pharma by 5.1% in the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company's stock worth $13,520,000 after purchasing an additional 413,162 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of aTyr Pharma by 79.4% in the first quarter. Alyeska Investment Group L.P. now owns 2,473,154 shares of the biotechnology company's stock worth $5,194,000 after buying an additional 1,094,407 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of aTyr Pharma by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 2,368,454 shares of the biotechnology company's stock worth $3,340,000 after acquiring an additional 84,848 shares in the last quarter. Samsara BioCapital LLC acquired a new position in shares of aTyr Pharma during the 1st quarter valued at about $3,675,000. Finally, BlackRock Inc. increased its holdings in shares of aTyr Pharma by 316.2% during the 2nd quarter. BlackRock Inc. now owns 1,370,159 shares of the biotechnology company's stock valued at $2,960,000 after acquiring an additional 1,040,982 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.